157 related articles for article (PubMed ID: 15688619)
21. Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove.
Takebayashi Y; Pourquier P; Yoshida A; Kohlhagen G; Pommier Y
Proc Natl Acad Sci U S A; 1999 Jun; 96(13):7196-201. PubMed ID: 10377391
[TBL] [Abstract][Full Text] [Related]
22. Some hope from marine natural products.
D'Incalci M
Ann Oncol; 1998 Sep; 9(9):937-8. PubMed ID: 9818065
[No Abstract] [Full Text] [Related]
23. DNA and non-DNA targets in the mechanism of action of the antitumor drug trabectedin.
David-Cordonnier MH; Gajate C; Olmea O; Laine W; de la Iglesia-Vicente J; Perez C; Cuevas C; Otero G; Manzanares I; Bailly C; Mollinedo F
Chem Biol; 2005 Nov; 12(11):1201-10. PubMed ID: 16298299
[TBL] [Abstract][Full Text] [Related]
24. Phthalascidin, a synthetic antitumor agent with potency and mode of action comparable to ecteinascidin 743.
Martinez EJ; Owa T; Schreiber SL; Corey EJ
Proc Natl Acad Sci U S A; 1999 Mar; 96(7):3496-501. PubMed ID: 10097064
[TBL] [Abstract][Full Text] [Related]
25. [Progress in the studies on antitumor natural product ecteinascidin-743].
Wang Y; Liu ZZ; Chen SZ; Liang XT
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Aug; 26(4):474-8. PubMed ID: 15379280
[TBL] [Abstract][Full Text] [Related]
26. Enantioselective synthesis of saframycin A and evaluation of antitumor activity relative to ecteinascidin/saframycin hybrids.
Martinez EJ; Corey EJ
Org Lett; 1999 Jul; 1(1):75-7. PubMed ID: 10822537
[TBL] [Abstract][Full Text] [Related]
27. The molecular mechanisms responsible for resistance to ET-743 (Trabectidin; Yondelis) in the Ewing's sarcoma cell line, TC-71.
Manara MC; Perdichizzi S; Serra M; Pierini R; Benini S; Hattinger CM; Astolfi A; Bagnati R; D'Incalci M; Picci P; Scotlandi K
Int J Oncol; 2005 Dec; 27(6):1605-16. PubMed ID: 16273217
[TBL] [Abstract][Full Text] [Related]
28. [Ecteinascidin 743].
Lansiaux A; Bailly C
Bull Cancer; 1999 Feb; 86(2):139-41. PubMed ID: 10094523
[No Abstract] [Full Text] [Related]
29. Ecteinascidin-743 (ET-743): early test or effective treatment in soft tissue sarcomas?
Verweij J
J Clin Oncol; 2005 Aug; 23(24):5420-3. PubMed ID: 16109999
[No Abstract] [Full Text] [Related]
30. Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma.
Schöffski P; Wolter P; Clement P; Sciot R; De Wever I; Wozniak A; Stefan C; Dumez H
Future Oncol; 2007 Aug; 3(4):381-92. PubMed ID: 17661712
[TBL] [Abstract][Full Text] [Related]
31. Editorial comment on "In vitro toxicity of ET-743 and Aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors: comparison with the clinical results" by Albella and colleagues.
D'Incalci M
Eur J Cancer; 2002 Jul; 38(10):1297. PubMed ID: 12091058
[No Abstract] [Full Text] [Related]
32. Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104).
Romano M; Frapolli R; Zangarini M; Bello E; Porcu L; Galmarini CM; García-Fernández LF; Cuevas C; Allavena P; Erba E; D'Incalci M
Int J Cancer; 2013 Nov; 133(9):2024-33. PubMed ID: 23588839
[TBL] [Abstract][Full Text] [Related]
33. Antitumor activity- and gene expression-based profiling of ecteinascidin Et 743 and phthalascidin Pt 650.
Martinez EJ; Corey EJ; Owa T
Chem Biol; 2001 Dec; 8(12):1151-60. PubMed ID: 11755394
[TBL] [Abstract][Full Text] [Related]
34. Scientists are searching the seas for cancer drugs.
O'Hanlon LH
J Natl Cancer Inst; 2006 May; 98(10):662-3. PubMed ID: 16705115
[No Abstract] [Full Text] [Related]
35. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways.
Damia G; Silvestri S; Carrassa L; Filiberti L; Faircloth GT; Liberi G; Foiani M; D'Incalci M
Int J Cancer; 2001 May; 92(4):583-8. PubMed ID: 11304695
[TBL] [Abstract][Full Text] [Related]
36. Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells.
Soares DG; Machado MS; Rocca CJ; Poindessous V; Ouaret D; Sarasin A; Galmarini CM; Henriques JA; Escargueil AE; Larsen AK
Mol Cancer Ther; 2011 Aug; 10(8):1481-9. PubMed ID: 21622731
[TBL] [Abstract][Full Text] [Related]
37. In vitro radiosensitisation by trabectedin in human cancer cell lines.
Romero J; Zapata I; Córdoba S; Jimeno JM; López-Martín JA; Tercero JC; De La Torre A; Vargas JA; Molerón R; Sánchez-Prieto R
Eur J Cancer; 2008 Aug; 44(12):1726-33. PubMed ID: 18501589
[TBL] [Abstract][Full Text] [Related]
38. Further insight into the DNA recognition mechanism of trabectedin from the differential affinity of its demethylated analogue ecteinascidin ET729 for the triplet DNA binding site CGA.
Marco E; David-Cordonnier MH; Bailly C; Cuevas C; Gago F
J Med Chem; 2006 Nov; 49(23):6925-9. PubMed ID: 17154523
[TBL] [Abstract][Full Text] [Related]
39. Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation.
Jin S; Gorfajn B; Faircloth G; Scotto KW
Proc Natl Acad Sci U S A; 2000 Jun; 97(12):6775-9. PubMed ID: 10841572
[TBL] [Abstract][Full Text] [Related]
40. In vitro toxicity of ET-743 and aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors. comparison with the clinical results.
Albella B; Faircloth G; López-Lázaro L; Guzmán C; Jimeno J; Bueren JA
Eur J Cancer; 2002 Jul; 38(10):1395-404. PubMed ID: 12091072
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
